Witnessing the stock’s movement on the chart, on Wednesday, Beam Therapeutics Inc (NASDAQ: BEAM) set off with pace as it heaved 1.99% to $23.02, before settling in for the price of $22.57 at the close. Taking a more long-term approach, BEAM posted a 52-week range of $16.95-$49.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare sector firm’s twelve-monthly sales growth has been 43297.50% for the last half of the decade. Meanwhile, its Annual Earning per share during the time was 5.58%. Nevertheless, stock’s Earnings Per Share (EPS) this year is -175.82%. This publicly-traded company’s shares outstanding now amounts to $81.63 million, simultaneously with a float of $76.84 million. The organization now has a market capitalization sitting at $1.89 billion. At the time of writing, stock’s 50-day Moving Average stood at $23.60, while the 200-day Moving Average is $26.62.
Beam Therapeutics Inc (BEAM) Ownership Facts and Figures
Nothing is more important than checking the behaviour of major investors towards the stock of the Biotechnology industry. Beam Therapeutics Inc’s current insider ownership accounts for 6.65%, in contrast to 78.70% institutional ownership. According to the most recent insider trade that took place on Jul 02 ’24, this organization’s Chief Medical Officer sold 748 shares at the rate of 22.95, making the entire transaction reach 17,167 in total value, affecting insider ownership by 68,805. Preceding that transaction, on Jul 01 ’24, Company’s Chief Medical Officer sold 502 for 23.76, making the whole transaction’s value amount to 11,928. This particular insider is now the holder of 69,553 in total.
Beam Therapeutics Inc (BEAM) Earnings and Revenue Records
Beam Therapeutics Inc’s EPS decrease for this current 12-month fiscal period is -175.82% and is forecasted to reach -4.77 in the upcoming year. Considering the longer run, market analysts have predicted that Company’s EPS will decrease by -3.70% through the next 5 years, which can be compared against the 5.58% growth it accomplished over the previous five years trading on the market.
Beam Therapeutics Inc (NASDAQ: BEAM) Trading Performance Indicators
Let’s observe the current performance indicators for Beam Therapeutics Inc (BEAM). It’s Quick Ratio in the last reported quarter now stands at 5.99. The Stock has managed to achieve an average true range (ATR) of 1.29. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 5.25.
In the same vein, BEAM’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.78, a figure that is expected to reach -1.14 in the next quarter, and analysts are predicting that it will be -4.77 at the market close of one year from today.
Technical Analysis of Beam Therapeutics Inc (BEAM)
Going through the that latest performance of [Beam Therapeutics Inc, BEAM]. Its last 5-days volume of 1.53 million indicated improvement to the volume of 1.39 million it revealed a year ago. During the previous 9 days, stock’s Stochastic %D was recorded 27.07% While, its Average True Range was 1.25.
Raw Stochastic average of Beam Therapeutics Inc (BEAM) in the period of the previous 100 days is set at 9.21%, which indicates a major fall in contrast to 28.74% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 50.83% that was lower than 71.10% volatility it exhibited in the past 100-days period.
